Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)
Unknown status
Chong Kun Dang Pharmaceutical
Phase 2
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and
50mg tid in active rheumatoid arthritis patients unsuccessfully treated with
disease-modifying antirheumatic drug.
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
Completed
Asahi Kasei Pharma Corporation
Phase 3
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of
standard therapy CTX through analyzing overall remission rate after treatment.
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
Completed
Asahi Kasei Pharma Corporation
Phase 3
To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is
non-inferior to that of standard therapy CTX through analyzing overall remission rate after
treatment.
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Completed
Regeneron Pharmaceuticals
Phase 3
Primary Objective:
To document the long-term safety of sarilumab added to non-methotrexate (non-MTX)
disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
Secondary Objective:
To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Completed
Sanofi
Phase 3
Primary Objective:
To document the long-term safety of sarilumab added to non-methotrexate (non-MTX)
disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
Secondary Objective:
To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
